AbbVie Inc. $ABBV Shares Sold by CX Institutional

CX Institutional trimmed its holdings in AbbVie Inc. (NYSE:ABBV) by 45.3% in the third quarter, HoldingsChannel.com reports. The institutional investor owned 42,843 shares of the company’s stock after selling 35,443 shares during the period. CX Institutional’s holdings in AbbVie were worth $11,207,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors also recently made changes to their positions in ABBV. Corient Private Wealth LP acquired a new stake in AbbVie during the 2nd quarter valued at $559,736,000. Legal & General Group Plc bought a new position in AbbVie during the second quarter worth $2,905,952,000. Capital World Investors increased its holdings in shares of AbbVie by 106.3% in the fourth quarter. Capital World Investors now owns 13,071,444 shares of the company’s stock valued at $2,986,777,000 after purchasing an additional 6,736,161 shares during the last quarter. Jupiter Topco LLC acquired a new position in shares of AbbVie in the second quarter valued at $1,560,354,000. Finally, Cardano Risk Management B.V. raised its position in shares of AbbVie by 914.6% in the fourth quarter. Cardano Risk Management B.V. now owns 5,444,930 shares of the company’s stock valued at $1,244,112,000 after purchasing an additional 4,908,260 shares during the period. 70.23% of the stock is currently owned by institutional investors.

Key Headlines Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: The FDA approved AbbVie’s new Parkinson’s disease pill, Juvmo, with a commercial launch targeted for October 2026. The product expands AbbVie’s neuroscience portfolio and could provide another source of growth beyond its immunology franchise. FDA approves AbbVie’s Juvmo for Parkinson’s Disease
• Positive Sentiment: Analysts’ consensus price target was reportedly raised 10.06% to MX$5,190.34, reinforcing bullish expectations. Separately, one analysis estimated that ABBV could be 41% undervalued following the Juvmo approval, although valuation models are inherently subjective. AbbVie consensus price target increased
• Positive Sentiment: New long-term data showed AbbVie’s RINVOQ continued to improve facial and total-body repigmentation in non-segmental vitiligo patients through week 76. The findings may strengthen RINVOQ’s commercial opportunity, though safety, reimbursement and competitive considerations remain important. AbbVie presents long-term RINVOQ data
• Neutral Sentiment: AbbVie will report third-quarter 2026 results before the market opens on October 30. The event gives investors a near-term catalyst to assess Skyrizi and Rinvoq growth, the post-Humira transition and management’s outlook. AbbVie third-quarter 2026 earnings conference call
• Neutral Sentiment: An update on an ongoing Greek clinical study is evaluating venetoclax in acute myeloid leukemia. The study remains an incremental pipeline development rather than a definitive efficacy or regulatory catalyst. AbbVie’s Venetoclax AML study update
• Negative Sentiment: AbbVie agreed to participate in a U.S. government pilot testing a new prescription-drug rebate system. While participation could improve relations with policymakers and potentially expand access, changes to rebates and pricing may create uncertainty around net drug prices and margins. AbbVie joins U.S. government pilot to test drug discount rebates
• Negative Sentiment: Despite strong recent performance, investors continue to weigh AbbVie’s elevated valuation, Humira revenue erosion and competition affecting its growth outlook. These risks could limit further upside even as newer products gain traction.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on ABBV shares. Morgan Stanley restated an “overweight” rating and set a $296.00 target price (up from $278.00) on shares of AbbVie in a research note on Monday, August 3rd. BNP Paribas Exane upped their price target on shares of AbbVie from $218.00 to $247.00 and gave the company a “neutral” rating in a research note on Tuesday, August 11th. Leerink Partners increased their price target on shares of AbbVie from $245.00 to $279.00 and gave the company an “outperform” rating in a report on Wednesday, August 5th. UBS Group raised their price objective on shares of AbbVie from $230.00 to $260.00 and gave the stock a “neutral” rating in a research report on Monday, July 13th. Finally, JPMorgan Chase & Co. boosted their price objective on AbbVie from $280.00 to $285.00 and gave the stock an “overweight” rating in a report on Thursday, July 30th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and six have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $272.66.

AbbVie Stock Up 1.3%

Shares of ABBV traded up $3.34 during midday trading on Friday, reaching $263.27. 5,562,834 shares of the stock were exchanged, compared to its average volume of 6,439,403. The stock’s 50 day simple moving average is $257.79 and its 200 day simple moving average is $234.39. The company has a market cap of $465.14 billion, a P/E ratio of 74.37, a PEG ratio of 1.19 and a beta of 0.24. AbbVie Inc. has a twelve month low of $190.75 and a twelve month high of $269.39.

AbbVie (NYSE:ABBV) last released its quarterly earnings results on Friday, July 31st. The company reported $3.65 EPS for the quarter, beating the consensus estimate of $3.61 by $0.04. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. The business had revenue of $16.99 billion for the quarter, compared to the consensus estimate of $16.80 billion. During the same period in the prior year, the company posted $2.97 earnings per share. AbbVie’s revenue was up 10.2% compared to the same quarter last year. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. As a group, analysts predict that AbbVie Inc. will post 14.05 earnings per share for the current year.

AbbVie Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, November 16th. Shareholders of record on Thursday, October 15th will be given a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a dividend yield of 2.6%. The ex-dividend date is Thursday, October 15th. AbbVie’s dividend payout ratio is presently 195.48%.

Insider Activity at AbbVie

In other news, EVP Nicholas Donoghoe sold 32,710 shares of AbbVie stock in a transaction that occurred on Friday, August 14th. The shares were sold at an average price of $250.00, for a total value of $8,177,500.00. Following the completion of the sale, the executive vice president directly owned 74,430 shares in the company, valued at approximately $18,607,500. The trade was a 30.53% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 0.06% of the company’s stock.

AbbVie Profile

AbbVie Inc is a global biopharmaceutical company that develops, manufactures and markets medicines for a range of serious and chronic health conditions. Its portfolio spans immunology, oncology, neuroscience, eye care, aesthetics, gastroenterology and women’s health.

The company’s products include the immunology medicines Skyrizi and Rinvoq; neuroscience treatments such as Vraylar, Ubrelvy and Qulipta; and oncology medicines including Imbruvica and Venclexta. AbbVie also markets Botox Cosmetic and Botox Therapeutic, as well as other products for aesthetics, eye care and specialty care.

AbbVie was established in 2013 as an independent, publicly traded company following its separation from Abbott Laboratories.